Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer

Louise R. Howe, Kotha Subbaramaiah, Jay Patel, Jaime L. Masferrer, Aparna Deora, Clifford Hudis, Howard T. Thaler, William J. Muller, Baoheng Du, Anthony M.C. Brown, Andrew J. Dannenberg

Research output: Contribution to journalArticlepeer-review

191 Scopus citations

Abstract

Cyclooxygenase 2 (HER-2) (Cox-2), an inducible form of Cox, is over-expressed in HER-2/neu-positive human breast cancers. The aim of this study was to determine whether celecoxib, a selective Cox-2 inhibitor, protected against HER-2/neu-induced experimental breast cancer. Cox-2 protein was detected in breast carcinomas from mouse mammary tumor virus (MMTV)/neu mice. Treatment with celecoxib (500 ppm) significantly reduced the incidence of mammary tumors in MMTV/neu mice (P = 0.003) and caused about a 50% reduction in mammary prostaglandin E2 (PGE2) levels. Because mammary glands from MMTV/neu mice expressed all four PGE2 receptor subtypes, we speculate that signaling through PGE2 receptors is important for mammary tumorigenesis. These results strengthen the rationale for developing clinical trials to determine whether selective Cox-2 inhibitors possess anticancer properties in humans at risk for breast cancer.

Original languageEnglish (US)
Pages (from-to)5405-5407
Number of pages3
JournalCancer research
Volume62
Issue number19
StatePublished - Oct 1 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer'. Together they form a unique fingerprint.

Cite this